I feel inspired to share on the Updates thread a few uplifting comments I received from readers in the past week. Following my admonition to a previous commenter that sending out short, supportive emails to hair growth companies (without asking for extra information that you know they are not ready to share) would be a worthwhile endeavor and boost morale, I received some encouraging responses from two frequent visitors of this site who followed through on the idea. Their comments are shared below. 🙂
A study led by Dr. Noha Doghaim of Tanta University in Egypt showed that carboxytherapy may be a promising treatment option for both alopecia areata and androgenic alopecia. The study comprised 80 subjects who were treated over the period of three months with either placebo or carboxytherapy. Both groups found favorable results from the carboxytherapy, however during a follow-up examination the improvements in androgenic alopecia subjects had decreased over time. The researchers noted that continual treatments would be necessary to maintain and bolster the benefits for AGA.
Certainly a company with a unique background and game plan, HairClone has received some recent media attention. The UK biotech startup was featured in this month’s publication of “Consulting Room” online magazine. In the article both Dr. Bessam Farjo and Paul Kemp of HairClone provided insight as to the company’s current progress and plans for the future. Things seem to be coming along well for HairClone and we should expect to hear from them again within the next several weeks. Full story is on Articles main page.
Dr. Carlos Wesley, a hair restoration surgeon in Manhattan, said that women in his practice respond better to P.R.P. than men do, which may have something to do with the fact that women with genetic hair loss tend to have more inflammatory cells around the follicles. From 2013 to 2014, he said, he had an 83 percent increase in female patients, in part because of P.R.P.
Patients with hair loss will often consult their family physician first. Hair loss is not life threatening, but it is distressing and significantly affects the patient's quality of life. The pattern of hair loss may be obvious, such as the bald patches that occur in alopecia areata, or more subtle, such as the diffuse hair loss that occurs in telogen effluvium. As with most conditions, the physician should begin the evaluation with a detailed history and physical examination. It is helpful to determine whether the hair loss is nonscarring (also called noncicatricial), which is reversible, or scarring (also called cicatricial), which is permanent. Scarring alopecia is rare and has various etiologies, including autoimmune diseases such as discoid lupus erythematosus. If the follicular orifices are absent, the alopecia is probably scarring; these patients should be referred to a dermatologist. This article will discuss approaches to nonscarring causes of alopecia.
The cause of female-pattern hair loss is unknown, but doctors said there is a strong genetic component. The risk can come from male or female relatives. Though it looks as if the hair is falling out, that's not really what's happening. Cotsarelis said hair follicles are becoming smaller and producing hairs that may be so small that you can't see them. Women tend to retain more normal, thick hairs than balding men do.
Hair loss is common in men as they grow older although it can affect them at any age. This can speed up for many different reasons although hormone related male pattern baldness is the most common of these. The most common symptom for men is a receding hairline, you can combat further receding with treatments ranging from oral supplements, prescription serums, and shampoos. We have a guide to the best hair growth supplements that has additional information
Dupilumab is FDA approved for treating eczema aka atopic dermatitis and sold under the brand name Dupixent. As the story goes, a patient with alopecia totalis (a form of areata which leaves a person’s head completely bald) was being treated for eczema by the drug Dupixent. After 6 weeks the patient first began to notice progress in terms of hair growth and at 7 months she had noticeable pigmented hair growth on her scalp. Notably, the patient stopped taking the dupilumab for a period of time and noticed her growth subsided; when she began taking the drug again the hair improved once more. This provides another useful therapy option for patients seeking treatment for AA. One would imagine a topical version would be worthwhile to investigate.
You might be surprised to know that some of those shampoos, conditioners, and styling agents have harsh chemicals that do a number on your hair. You may want to consider switching to softer hair care products that are designed to slow down hair thinning in men. DHT-blocking shampoos and conditioners containing ingredients such as ketoconazole and pyrithione zinc have shown some promise in helping reverse hair loss by potentially disrupting the production of DHT, the hormone linked to male pattern baldness. These
2. Oil-rich conditioner. “Oils improve hair’s tensile strength,” says Paradi Mirmirani, a hair-loss specialist and dermatologist in Vallejo, California. In other words, oils make hair less likely to break under pressure, which is especially important for thinning hair that’s prone to snapping when brushed or styled. Mirmirani recommends using a conditioner fortified with natural oils, like Burt’s Bees Very Volumizing Pomegranate Conditioner, which contains avocado oil ($8), or Honest Company Conditioner with coconut oil ($10). That one’s got an added benefit: “Coconut oil has been shown to penetrate hair,” says cosmetic chemist Randy Schueller, so it makes your hair stronger from the inside out. (Just don’t load up on pure coconut oil. “You might overshampoo your hair to get it out, and then you’ll end up drying your hair and undoing any benefit,” says Fusco.)
In Vancouver, a Canadian company called RepliCel focusses on the hair follicle’s “dermal-sheath cup cells,” its C.E.O., Lee Buckler, explained. Buckler believes that DHT attacks these cup cells “like a parasite.” Like Histogen, RepliCel’s consumer product would be an injectable. The company would generate new versions of your cup cells, which would be implanted into your “affected area”—the places where your hair has fallen out. Boom: new hairs. (Theoretically.)
“Regenerative medicine is a game-changing area of medicine with the potential to fully heal damaged tissues and organs, offering solutions and hope for people who have conditions that today are beyond repair,” Buckler said. “RepliCel is one of the most promising biotech companies to watch in the field of developing medical innovations that are life-changing.”
The Rogaine rep we spoke to explained that the different packaging (and therefore different prices) has to do with the FDA-approval process: “We discovered in clinical trials that the hair loss patterns between men and women are different,” she said by way of explanation. “Men typically have that bald spot on the crown of their head, where women generally have a general thinning throughout, but concentrated more on the top of the head. So for FDA approval, we had to come up with two different, gender-specific products, so the directions were more explanatory.”
Disruptions in the normal length of each phase, which can cause hair loss and hair thinning, may be the result of a number of internal and external stimuli. These are also what we call the triggers and causes of your hair loss. As a quick example, dieting can leave the body stressed and in need of important nutrients. Because of this stress, hair growth may be cut shorter than usual and there is an early onset of telogen or shedding of hair.
Because there are a lot of products in the crowded marketplace that claim they can regrow your hair, it’s a necessity for the legitimate ones to have disclaimers on their websites. Essentially, these disclaimers state that the products haven’t been evaluated by the FDA and so can’t be guaranteed to provide the benefits they claim to provide—at least not from the standpoint of the regulators.